All Updates

All Updates

icon
Filter
M&A
Eli Lilly acquires Morphic Holding for USD 3.2 billion to expand immunology pipeline
Precision Medicine
Jul 8, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Jul 11, 2024
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Jul 11, 2024
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Jul 11, 2024
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Jul 11, 2024
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Jul 11, 2024
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Jul 11, 2024
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Jul 11, 2024
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Jul 11, 2024
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Jul 11, 2024
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Jul 11, 2024
Precision Medicine

Precision Medicine

Jul 8, 2024

Eli Lilly acquires Morphic Holding for USD 3.2 billion to expand immunology pipeline

M&A

  • Eli Lilly has announced the acquisition of Morphic Holding, a biopharmaceutical company specializing in oral integrin therapies for chronic diseases. As per the definitive agreement, Lilly will acquire all outstanding shares of Morphic for USD 57 per share. The transaction is valued at ~USD 3.2 billion and is expected to close in Q3 2024.

  • Post-acquisition, Lilly plans to expand its immunology portfolio and develop new therapies in gastroenterology. Morphic's main product is an oral molecule known as "MORF-057," which inhibits α4β7 integrin, a protein implicated in inflammatory bowel disease. It is being tested in two Phase II trials for ulcerative colitis and Phase I trials for Crohn's disease. 

  • Eli Lilly and Company is a global pharmaceutical company committed to creating high-quality medicines that address unmet medical needs. The company is focused on neuroscience, cardiometabolic, cancer, and immunology disease areas. Key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, Humulin for diabetes, and Taltz and Olumiant for immunology.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.